Aaron Mangold, MD, discusses phase 2 BEACON data on brepocitinib, a TYK2/JAK1 inhibitor, in cutaneous sarcoidosis presented at EADV 2026.
Aaron R. Mangold, MD
Advertisement
Associate professor, Mayo Clinic
Articles by Aaron R. Mangold, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD
2
Tips on Optimizing HS Biologics, Combinations, and Surgery
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis
5